Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach

References

• Global initiative for asthma. Global strategy for asthma management and prevention; 2021. Available from: https://ginasthma.org/gina-reports/. Accessed July 1, 2021.
   Google Scholar
• Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042
   PubMed Web of Science ®Google Scholar
• Frøssing L, Silberbrandt A, Von Bülow A, Backer V, Porsbjerg C. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma. J Allergy Clin Immunol Pract. 2021;9(3):1267–1275. doi:10.1016/j.jaip.2020.09.051
   PubMed Web of Science ®Google Scholar
• Matsusaka M, Fukunaga K, Kabata H, Izuhara K, Asano K, Betsuyaku T. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6(1):274–e276.e2. doi:10.1016/j.jaip.2017.06.015
   Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (Sirocco): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190. doi:10.1067/mai.2001.117880
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.e7. doi:10.1016/j.jaci.2018.09.033
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Akenroye A, McCormack M, Keet C. Severe asthma in the US population and eligibility for mAb therapy. J Allergy Clin Immunol. 2020;145(4):1295–1297.e6. doi:10.1016/j.jaci.2019.12.009
   PubMed Web of Science ®Google Scholar
• Wu AC, Busse WW. Biologic therapy in allergy practice: a new era in treatment has begun. J Allergy Clin Immunol Pract. 2021;9(3):1118–1120. doi:10.1016/j.jaip.2020.12.036
   Web of Science ®Google Scholar
• Fong WCG, Azim A, Knight D, et al. Real-world omalizumab and mepolizumab treated difficult asthma phenotypes and their clinical outcomes. Clin Exp Allergy. 2021;51(8):1019–1032. doi:10.1111/cea.13882
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, et al. Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:10.1016/j.chest.2020.08.2083
   PubMed Web of Science ®Google Scholar
• Harvey ES, Langton D, Katelaris C, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:10.1183/13993003.02420-2019
   PubMed Web of Science ®Google Scholar
• Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-term therapy response to anti-IL-5 biologics in severe asthma-a real-life evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194–1200. doi:10.1016/j.jaip.2020.10.010
   PubMed Web of Science ®Google Scholar
• Anderson WC 3rd, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367–372. doi:10.1016/j.anai.2019.01.018
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2. doi:10.1016/j.jaci.2016.08.054
   PubMed Web of Science ®Google Scholar
• Vennera MDC, Sabadell C, Picado C. Spanish omalizumab registry. duration of the efficacy of omalizumab after treatment discontinuation in “real life” severe asthma. Thorax. 2018;73(8):782–784. doi:10.1136/thoraxjnl-2017-210017
   Web of Science ®Google Scholar
• Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133(3):921–923. doi:10.1016/j.jaci.2013.11.026
   PubMed Web of Science ®Google Scholar
• Ortega H, Lemiere C, Llanos JP, et al. Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. Allergy Asthma Clin Immunol. 2019;15:37. doi:10.1186/s13223-019-0348-z
   PubMed Web of Science ®Google Scholar
• Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2021:2100396. doi:10.1183/13993003.00396-2021
   Web of Science ®Google Scholar
• Jeffery MM, Inselman JW, Maddux JT, Lam RW, Shah ND, Rank MA. Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics. J Allergy Clin Immunol Pract. 2021;9(7):2742–2750.e1. doi:10.1016/j.jaip.2021.02.031
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.008
   PubMed Web of Science ®Google Scholar
• Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying “well-controlled” and “not well-controlled” asthma using the asthma control questionnaire. Respir Med. 2006;100(4):616–621. doi:10.1016/j.rmed.2005.08.012
   PubMed Web of Science ®Google Scholar
• Ludviksdottir D, Diamant Z, Alving K, Bjermer L, Malinovschi A. Clinical aspects of using exhaled NO in asthma diagnosis and management. Clin Respir J. 2012;6(4):193–207. doi:10.1111/crj.12001
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Kuwahira I, Hanaoka M, et al. An official JRS statement: the principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice. Respir Investig. 2021;59(1):34–52. doi:10.1016/j.resinv.2020.05.006
   PubMed Web of Science ®Google Scholar
• Hearn AP, Kavanagh J, d’Ancona G, et al. The relationship between feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(5):2093–2096.e1. doi:10.1016/j.jaip.2021.01.008
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Marchewski H, Schwefel G, Stoll P, Virchow JC, Bratke K. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma. Clin Exp Allergy. 2020;50(11):1267–1269. doi:10.1111/cea.13720
   PubMed Web of Science ®Google Scholar
• Sehmi R, Lim HF, Mukherjee M, et al. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J Allergy Clin Immunol. 2018;141(4):1529–1532.e8. doi:10.1016/j.jaci.2018.01.008
   PubMed Web of Science ®Google Scholar
• Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33(4):897–906. doi:10.1183/09031936.00121308
   PubMed Web of Science ®Google Scholar
• Hamada K, Oishi K, Chikumoto A, et al. Impact of sinus surgery on type 2 airway and systemic inflammation in asthma. J Asthma. 2021;58(6):750–758. doi:10.1080/02770903.2020.1729380
   PubMed Web of Science ®Google Scholar
• Upham JW, Le Lievre C, Jackson DJ, et al. Defining a severe asthma super-responder: findings from a delphi process. J Allergy Clin Immunol Pract. 2021;9(11):3997–4004. doi:10.1016/j.jaip.2021.06.041
   PubMed Web of Science ®Google Scholar
• Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–1437. doi:10.1136/annrheumdis-2016-209201
   PubMed Web of Science ®Google Scholar
• Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology. 2004;43(10):1252–1255. doi:10.1093/rheumatology/keh297
   PubMed Web of Science ®Google Scholar
• Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796–R806. doi:10.1186/ar1740
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42(2):244–257. doi:10.1093/rheumatology/keg072
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Szefler SJ, Mauger DT, et al. Development and initial validation of the Asthma Severity Scoring System (ASSESS). J Allergy Clin Immunol. 2020;145(1):127–139. doi:10.1016/j.jaci.2019.09.018
   PubMed Web of Science ®Google Scholar
• Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the composite asthma severity index–an outcome measure for use in children and adolescents. J Allergy Clin Immunol. 2012;129(3):694–701. doi:10.1016/j.jaci.2011.12.962
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Hamada K, Oishi K, Yano M, Yamaji Y, Hirano T. Factors associated with physician–patient discordance in the perception of asthma control. J Allergy Clin Immunol Pract. 2019;7(8):2634–2641. doi:10.1016/j.jaip.2019.04.046
   PubMed Web of Science ®Google Scholar
• Hirata S, Saito K, Kubo S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013;15(5):R135. doi:10.1186/ar4315
   PubMed Web of Science ®Google Scholar
• Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918–929. doi:10.1016/S0140-6736(12)61811-X
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389–395. doi:10.1136/annrheumdis-2013-204016
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):164. doi:10.1186/s13075-019-1937-4
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286–1291. doi:10.1136/ard.2009.121491
   PubMed Web of Science ®Google Scholar